Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Virios Therapeutics Inc (NQ: VIRI ) 0.1940 +0.0140 (+7.78%) Streaming Delayed Price Updated: 3:58 PM EDT, Aug 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Virios Therapeutics Inc < Previous 1 2 Next > Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal April 25, 2023 Virios Therapeutics Inc. (NASDAQ: VIRI) is a developmental-stage biotechnology company specializing in novel antiviral therapies for treating fibromyalgia Via MarketBeat Exposures Product Safety Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase November 29, 2022 From Virios Therapeutics, Inc. (VIRI) Via Business Wire Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update November 14, 2022 From Virios Therapeutics, Inc. Via Business Wire Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022 November 03, 2022 From Virios Therapeutics, Inc. (VIRI) Via Business Wire Virios Therapeutics, Inc. Announces Closing of Public Offering September 22, 2022 From Virios Therapeutics, Inc. Via Business Wire Virios Therapeutics, Inc. Announces Pricing of Public Offering September 19, 2022 From Virios Therapeutics, Inc. Via Business Wire Virios Therapeutics, Inc. Announces Proposed Public Offering September 19, 2022 From Virios Therapeutics, Inc. Via Business Wire Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia September 19, 2022 From Virios Therapeutics, Inc. (VIRI) Via Business Wire Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial August 15, 2022 From Virios Therapeutics, Inc. (VIRI) Via Business Wire Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update August 11, 2022 From Virios Therapeutics, Inc. Via Business Wire Virios Therapeutics, Inc. to Present at Investor Summit Group’s Q3 Virtual Conference August 10, 2022 From Virios Therapeutics, Inc. Via Business Wire Virios Therapeutics: The 'Virus Hypothesis' That Stands to Change the Lives of 10M Americans August 09, 2022 Via ACN Newswire Virios Therapeutics: The 'Virus Hypothesis' That Stands to Change the Lives of 10M Americans August 08, 2022 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Virios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August 11, 2022 August 04, 2022 From Virios Therapeutics, Inc. Via Business Wire Virios Therapeutics (Nasdaq: VIRI) Advancing Potential Paradigm Shift in Fibromyalgia Treatment July 26, 2022 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Virios' Promising Fibromyalgia Treatment Candidate Expects September 2022 Phase 2b Results July 19, 2022 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Virios Therapeutics’ Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patients with Comorbid Fibromyalgia June 01, 2022 From Virios Therapeutics, Inc. Via Business Wire Virios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update May 12, 2022 From Virios Therapeutics, Inc. Via Business Wire Virios Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on Thursday, May 12, 2022 May 05, 2022 From Virios Therapeutics, Inc. Via Business Wire Virios Therapeutics Completes Enrollment of 425 Patients in Phase 2b “FORTRESS” Clinical Trial for Fibromyalgia April 28, 2022 From Virios Therapeutics, Inc. (VIRI) Via Business Wire Virios Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update March 17, 2022 From Virios Therapeutics, Inc. Via Business Wire Virios Therapeutics Announces Research Collaboration Exploring the Potential of Combination Antiviral Therapy for Treating Long COVID February 28, 2022 From Virios Therapeutics, Inc. (VIRI) Via Business Wire RedChip Partners with Benzinga to Host Exclusive Small-Cap CEO Interview Series on January 28 January 26, 2022 ORLANDO, FL / ACCESSWIRE / January 26, 2022 / RedChip Companies, Inc., an international investor relations, media, and research firm focused on microcap and small-cap companies, is pleased to announce... From RedChip Via AccessWire Virios Therapeutics to Present at the Virtual H.C. Wainwright BioConnect Conference January 04, 2022 From Virios Therapeutics, Inc. (VIRI) Via Business Wire Virios Therapeutics Achieves Over 50% Enrollment Milestone in its Phase 2b Clinical Trial for Fibromyalgia December 01, 2021 From Virios Therapeutics, Inc. (VIRI) Via Business Wire Virios Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update November 11, 2021 From Virios Therapeutics, Inc. (VIRI) Via Business Wire Virios Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on Thursday, November 11, 2021 November 04, 2021 From Virios Therapeutics, Inc. (VIRI) Via Business Wire Virios Therapeutics Granted New Patent for Antiviral Inhibitor Combination September 08, 2021 From Virios Therapeutics, Inc. Via Business Wire Virios Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 02, 2021 From Virios Therapeutics, Inc. (VIRI) Via Business Wire Virios Therapeutics Announces New Social Media Profiles August 19, 2021 From Virios Therapeutics, Inc. Via Business Wire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.